KOSPIBiotech & Pharma007570

Ilyang Pharmaceutical

₩6,240▼ 2.04%2026-11-18 close
Market Cap
₩119.1B
Turnover
₩100M
Volume
20K
Shares out.
19.1M
PER
9.5×
PBR
0.5×
EPS
₩664
Dividend Yield
2.46%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩155 per share · Prices as of the 2026-11-18 close

01

Report overview

Third-Quarter Turn to Profit, Core Recovery Still Pending

Ilyang Pharmaceutical returned to operating profit in the third quarter of 2026, but its cumulative operating loss for the first three quarters remains, so whether the core business recovers is the next point to track.

  1. 1

    Third-quarter 2026 revenue rose 16.7% year on year to KRW 80.3 billion, and operating profit of KRW 5.23 billion marked a swing back to profit.

  2. 2

    The cumulative operating loss for the first three quarters of 2026 was KRW 8.9 billion, and third-quarter net income included non-recurring inflows such as dividends and compensation from the Chinese subsidiary.

  3. 3

    The operating margin fell from 6.1% in 2023 to 1.8% in 2025, so the central question is why revenue growth has not translated into profit.

  4. 4

    Vaccines weighed on results through lower National Immunization Program supply and inventory losses, and GMP approval for the vaccine finishing line is the next variable.

  5. 5

    Accounting-related sanctions imposed in November 2025 and the change in the largest shareholder in July 2026 have overlapped, and governance and internal control remediation is under way.

02

Business structure

Ilyang Pharmaceutical was founded in 1946 and listed on the KOSPI market in 1974, and it holds subsidiaries including Ilyang Biopharm.

Its main products are the domestically developed anti-ulcer drug Noltec, the leukemia treatment Supect (radotinib), seasonal influenza vaccines among prescription drugs, and the OTC brand Wonbidi.

In cumulative revenue for the first three quarters of 2026, excluding intercompany sales, the prescription drug (ETC) segment contributed KRW 87.1 billion, or 41.37% of the total. The export segment reached KRW 42.8 billion, up 16.4% from KRW 36.8 billion a year earlier, and accounted for 20.33%.

The OTC segment recorded KRW 41.1 billion (19.53%), and other segments, including health supplements, recorded KRW 34.4 billion (16.33%). Noltec sits at the center of revenue and is described as expanding its prescription share as a core earnings source.

The vaccine business centers on influenza vaccines made at the Eumseong vaccine plant, which was completed in 2011, and its customers include the prescription market and government National Immunization Program (NIP) procurement volumes.

In the past, Chinese joint ventures were deeply tied to reported results, but in early 2025 the company restated its 2022 and 2023 annual reports and reclassified the two entities as jointly controlled companies rather than subsidiaries.

It has since been dismantling the joint-venture-centered structure, including transferring its stake in Tongwha Ilyang to the Chinese shareholder. On the competitive side, operating results in the first half of 2026 diverged across the sector.

Unlike traditional pharma companies such as Hanmi Pharm, whose operating profit grew faster than revenue, Ilyang Pharmaceutical moved from operating profit to operating loss.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩68.8B-₩200M−0.2%
2025Q4₩78.9B₩600M0.7%
2026Q1₩65.1B-₩7.4B−11.3%
2026Q2₩65.1B-₩6.8B−10.4%
2026Q3₩80.3B₩5.2B6.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩247.8B₩14.2B₩19.4B5.8%8.3%69.4%
2023₩266.7B₩16.4B-₩2.4B6.1%−1.1%70.4%
2024₩268.9B₩11B₩10.3B4.1%4.3%78.5%
2025₩272.4B₩5B₩6.9B1.8%2.9%89.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 247.8 billion in 2022 to KRW 266.7 billion in 2023 (up 7.6%), KRW 268.9 billion in 2024 (up 0.8%) and KRW 272.4 billion in 2025 (up 1.3%), growing for three consecutive years from 2023 through 2025.

The pace of growth narrowed to about 1% in 2024 and 2025, and 2025 was the largest year of the 2022–2025 period.

Operating profit went from KRW 14.2 billion in 2022 to KRW 16.4 billion in 2023 (up 14.9%), the peak of the period, before falling to KRW 11 billion in 2024 (down 32.8%) and KRW 4.96 billion in 2025 (down 54.9%), a two-year decline from 2024 through 2025.

The operating margin slid from 5.8% in 2022 and 6.1% in 2023 to 4.1% in 2024 and 1.8% in 2025.

The margin fell while revenue grew, which appears to reflect cost pressure: in the first half of 2026, the cost of sales ratio rose from 55.6% to 62.5%, and selling, general and administrative expenses increased from KRW 38.7 billion to KRW 48.2 billion.

Net income attributable to controlling shareholders went from KRW 19.4 billion in 2022 to a net loss of KRW 2.41 billion in 2023, a swing back to profit at KRW 10.3 billion in 2024, and KRW 6.9 billion in 2025 (down 32.7%). Reports attributed the 2024 recovery partly to the liquidation of a Chinese subsidiary.

Net income including non-controlling interests, a different figure, was KRW 7.13 billion in 2025. The debt-to-equity ratio climbed from 69.4% in 2022 to 89.4% in 2025.

At the end of 2025, total equity was KRW 241.4 billion, of which KRW 237.6 billion belonged to controlling shareholders, and total liabilities were KRW 215.9 billion.

Operating cash flow was KRW 5.88 billion in 2022, KRW 14.6 billion in 2023, KRW 5.61 billion in 2024 and KRW 12 billion in 2025, rising in 2025 even as operating profit fell.

Quarterly, the company moved from an operating loss of KRW 158 million in the third quarter of 2025 to operating profit of KRW 566 million in the fourth quarter (a swing to profit), then to an operating loss of KRW 7.37 billion in the first quarter of 2026 (a swing to loss), an operating loss of KRW 6.77 billion in the second quarter (loss continued, but narrowed), and operating profit of KRW 5.23 billion in the third quarter (a swing back to profit).

Revenue was KRW 65.1 billion in the first quarter of 2026, KRW 65.1 billion in the second (up 0.1% quarter on quarter), and KRW 80.3 billion in the third (up 23.3%), rising for two consecutive quarters.

Controlling shareholders' net income swung to KRW 16.8 billion in the first quarter of 2026, a period in which about KRW 24.5 billion of dividend income was reflected.

Net income attributable to controlling shareholders over the last four quarters (fourth quarter of 2025 to third quarter of 2026) totaled KRW 12.3 billion.

05

Industry analysis

Earnings diverged sharply even within the pharmaceutical and biotech sector. According to a 2026 first-half analysis, new-drug developers continued to post losses under the weight of R&D and overseas expansion costs.

Among traditional pharma companies, Hanmi Pharm grew operating profit faster than revenue, whereas Ilyang Pharmaceutical belonged to a group that, together with Shinpoong Pharm, Jeil Pharmaceutical and Chong Kun Dang Bio, moved from operating profit to operating loss in the first half.

The vaccine business depends heavily on government National Immunization Program (NIP) procurement volumes. Ilyang's NIP influenza vaccine supply contract fell 32% from KRW 20.9 billion in the 2024–2025 season to KRW 14.3 billion in the 2025–2026 season.

In the 2026–2027 season competitive bidding, the company bid for 1.5 million doses but was allocated 1.05 million, and its unit bid price was the highest and its allocated volume the smallest among the six winning bidders.

Some view vaccines as only about 5% of NIP contract value and therefore a limited impact, but the KRW 30 billion investment in the vaccine finishing line exceeds 20% of market capitalization and has been cited as a main driver of higher borrowings.

On inventory, the first-half 2026 inventory valuation loss of KRW 3.34 billion equaled 24% of the operating loss. Noltec remains the core earnings source in prescription drugs, so its prescription share is the main measure of the company's position against industry conditions. In China, delayed marketing approval for Supect has pushed back the timing of commercialization.

06

Outlook

A company official said the company spent a difficult period because of delayed commercialization of its Chinese drug business and regulatory uncertainty, but expects steady growth next year once one-time costs are resolved and the business transition is complete.

For that expectation to show up in results, the operating margin needs to stay positive quarter after quarter.

On vaccines, the finishing line is in equipment stabilization and the company is pursuing GMP approval, with trial production of influenza vaccines under way, and approval will be a turning point for production capacity and cost structure.

In products, Noltec Plus Mini tablets obtained approval, laying the groundwork to widen the lineup in digestive disorders such as gastroesophageal reflux disease.

In China, the company withdrew the new drug application for Supect and plans to re-file after selecting a new contract research organization, though approval delays and additional costs are expected.

Under its corporate value enhancement plan, the company has pursued governance steps such as ending overlapping directorships with affiliates, setting up ethics and executive compensation committees, and strengthening the audit committee.

The change in the largest shareholder was disclosed on July 30, 2026, and CEO Jung Yu-seok now holds the largest shareholder position alongside management control. A single-sales and supply contract termination was disclosed on September 9, 2026, and its revenue impact is a point to confirm in the next periodic report.

07

Valuation

PER
9.5×
PBR
0.5×
ROE
5.0%
EPS
₩664
BPS
₩13,642
Dividend per share
₩155

Valuation is easier to read when split into an earnings lens and an asset lens. The price-to-book ratio sits in a range below book value per share, which indicates a price at a discount to accounting equity.

On earnings, however, the company swung to operating profit in the third quarter of 2026 while a cumulative operating loss for the first three quarters remains, so the multiple depends more on one-time items in net income attributable to controlling shareholders than on core operating profit.

Net income attributable to controlling shareholders totaled KRW 12.3 billion over the last four quarters, and dividend income played a large role in the first quarter of 2026.

Across years, the company moved from a net loss in 2023 to profit in 2024, then saw net income fall 32.7% in 2025, so earnings-based multiples have shown wide swings.

With the debt-to-equity ratio rising from 69.4% in 2022 to 89.4% in 2025, the asset-based view should be read together with the change in capital structure.

On dividends, shareholder returns can move separately from the recovery in operating profit, so dividend capacity should be checked against the trend in operating cash flow.

For this stock, the recovery pace of earnings and the direction of debt burden are more relevant reference points than the share price level itself.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Third-quarter profit swing and revenue growth

Third-quarter 2026 revenue rose 16.7% year on year to KRW 80.3 billion, and operating profit of KRW 5.23 billion marked a swing to profit. Revenue has risen for two consecutive quarters since the first-quarter 2026 low. Quarterly confirmation of the operating turnaround is the main basis for this case.

Noltec and export-led earnings base

In cumulative revenue for the first three quarters of 2026, the prescription drug segment contributed KRW 87.1 billion, or 41.37%, and exports rose 16.4% to KRW 42.8 billion. Approval of Noltec Plus Mini tablets lays groundwork for a broader digestive-disease lineup. Growth in the core product and exports together forms the axis of the revenue recovery.

Joint-venture unwinding and better cash generation

Dividends and compensation from the Chinese joint venture supported net income in the first half of 2026, and operating cash flow rose to KRW 12 billion in 2025 from KRW 5.61 billion in 2024.

The company is unwinding its joint-venture-centered structure by transferring its Tongwha Ilyang stake and acquiring trademarks and rights related to Wonbidi. Completing this process would reduce structural uncertainty in the business.

09

Bear factors

Weakening core profitability

The operating margin fell from 6.1% in 2023 to 1.8% in 2025, and operating profit of KRW 4.96 billion in 2025 was down 54.9%. The operating loss in the first half of 2026 was KRW 14.1 billion, with the cost of sales ratio rising from 55.6% to 62.5% and selling, general and administrative expenses up 24.7%. The bear case rests on revenue growth failing to offset cost increases.

Net income leaning on non-recurring gains

In the first half of 2026, dividend income of KRW 26.9 billion made up most of KRW 27.5 billion in other gains, and net income of KRW 14.6 billion came despite an operating loss of KRW 14.1 billion. Cumulative net income through the third quarter also reflects dividends and compensation from the Chinese subsidiary. It is hard to attribute net income to a core business recovery.

Financial burden and pipeline delays

The debt-to-equity ratio rose from 69.4% in 2022 to 89.4% in 2025, and the current ratio stood at 90.3% in the third-quarter 2026 report. The KRW 30 billion vaccine finishing-line investment has been cited as a main reason for higher borrowings. In China, Supect's marketing application was withdrawn, pushing the approval timeline back.

10

Risk factors

Accounting and governance sanctions

Trading was suspended from September 10, 2025, and in November 2025 the Financial Services Commission imposed a total fine of KRW 7.49 billion, including a company fine of KRW 6.23 billion, along with a recommendation to dismiss co-CEOs, a six-month suspension of duties and a three-year designation of auditors.

The largest shareholder changed in July 2026. Whether internal control remediation takes hold is a follow-up item.

Vaccine volumes and inventory losses

The NIP influenza vaccine contract fell to KRW 14.3 billion in the 2025–2026 season, and the allocation for 2026–2027 was 1.05 million doses. The inventory valuation allowance rose to KRW 9.02 billion by the end of June 2026. If procurement volumes do not recover, inventory losses could recur.

Contract termination and legal costs

A single-sales and supply contract termination was disclosed on September 9, 2026, and its size affects the revenue base. Commission expenses, including legal advisory costs tied to the Chinese joint venture dispute, rose from KRW 3.9 billion in the first half of 2025 to KRW 10.4 billion in the first half of 2026.

Legal costs look largely one-off as the joint venture is unwound, but the termination could still reduce revenue.

11

What to watch next

  1. After December 2026 (date not set)

    Whether the vaccine finishing line receives GMP approval. Approval would mark a turning point for production capacity and cost structure.

  2. Around March 2027 (the 2025 annual report was filed on March 11, 2026)

    The 2026 annual report will show the full-year operating margin, the share of dividend income in net income attributable to controlling shareholders, and the trend in the debt-to-equity ratio.

  3. Mid-May 2027 (based on the May 15 release date for the first quarter of 2026)

    Whether operating profit stays positive in the first quarter of 2027 and whether NIP vaccine inventory losses recur.

  4. After December 2026 (re-filing timing not set)

    The timing of Supect's re-filing in China and the approval outcome, which determine when commercialization can begin there.

12

Overall view

Ilyang Pharmaceutical posted quarterly revenue of KRW 80.3 billion and operating profit of KRW 5.23 billion in the third quarter of 2026, a swing to profit, and revenue has risen for two consecutive quarters.

Yet the cumulative operating loss for the first three quarters of 2026 remains at KRW 8.9 billion, and the operating margin fell to 1.8% in 2025. One-time items such as Chinese joint-venture dividends and compensation contributed significantly to the net income recovery.

In vaccines, lower NIP volumes and inventory losses are weighing on results, and GMP approval for the finishing line is the next variable. The re-filing timeline for Supect in China and the prescription growth of Noltec are the two axes for improving the earnings structure.

On the financial side, the debt-to-equity ratio rose to 89.4%, and the accounting sanctions and governance changes of 2025 continue to shape the story. The next checkpoints are the full-year operating margin in the 2026 annual report and whether operating profit stays positive in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. ebn.co.kr
  2. kr.investing.com
  3. ebn.co.kr
  4. comp.wisereport.co.kr
  5. dailyan.com
  6. etoday.co.kr
  7. medipana.com
  8. kind.krx.co.kr
  9. vegannews.co.kr
  10. comp.wisereport.co.kr
  11. kr.investing.com
  12. dailypharm.com
  13. youthdaily.co.kr
  14. investing.com
  15. medipharmhealth.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis